Oral administration of dihomo-gamma-linolenic acid prevents development of atopic dermatitis in NC/Nga mice.
Disorders of the metabolism of essential fatty acids (EFAs) are related to atopic dermatitis (AD). Concentrations of dihomo-gamma-linolenic acid (DGLA), an EFA, in the serum of AD patients are lower than those in healthy volunteers. Recently we developed a fermented DGLA oil, and examined whether oral administration of DGLA prevents development of dermatitis in NC/Nga mice, which spontaneously develop human AD-like skin lesions. NC/Nga mice were fed a diet either containing or not containing DGLA for 8 weeks under in air-uncontrolled conventional circumstances. Clinical skin severity scores were significantly lower in mice fed DGLA than in mice not fed it. Scratching behavior and plasma total IgE levels were also reduced in the DGLA group, in association with histological improvement. DGLA suppressed clinical severity of skin lesions dose-dependently, with an increase in DGLA contents in phospholipids of skin, spleen, and plasma. Discontinuation of DGLA administration resulted in the onset of dermatitis and a decrease in DGLA contents in skin, spleen, and plasma. These findings indicate that oral administration of DGLA effectively prevents the development of AD in NC/Nga mice, and that DGLA in phospholipids is a compound of key importance in the development and prevention of dermatitis.
Kawashima
H
H
Institute for Health Care Science, Suntory Ltd, 1-1-1, Wakayamadai, Shimamoto-cho, Mishima-gun, Osaka 618-8503, Japan. hiroshi_kawashima@suntory.co.jp
Tateishi
N
N
Shiraishi
A
A
Teraoka
N
N
Tanaka
T
T
Tanaka
A
A
Matsuda
H
H
Kiso
Y
Y
D015126:8,11,14-Eicosatrienoic Acid / Q000008:administration & dosage*; D000284:Administration, Oral; D000818:Animals; D003876:Dermatitis, Atopic / Q000517:prevention & control*; D004032:Diet; D004195:Disease Models, Animal; D004305:Dose-Response Relationship, Drug; D005260:Female; D007073:Immunoglobulin E / Q000097:blood; D008297:Male; D051379:Mice; D008815:Mice, Inbred Strains; D012720:Severity of Illness Index; D012867:Skin / Q000187:drug effects / Q000473:pathology; D012882:Skin Tests
D007073:Immunoglobulin E; D015126:8,11,14-Eicosatrienoic Acid